Thermoreversible gel for delivery of activin receptor-like kinase 5 inhibitor SB-505124 for glaucoma filtration surgery

References

• Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983;101:795–798.
   PubMedGoogle Scholar
• Gorovoy M, Koga T, Shen X, Jia Z, Yue BY, Voyno-Yasenetskaya T. Downregulation of LIM kinase 1 suppresses ocular inflammation and fibrosis. Mol Vis 2008;14:1951–1959.
   PubMedGoogle Scholar
• Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 2002;62:58–64.
   PubMed Web of Science ®Google Scholar
• Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954–7961.
   PubMed Web of Science ®Google Scholar
• Sapitro J, Dunmire JJ, Scott SE, Sutariya V, Geldenhuys WJ, Hewit M et al. Suppression of transforming growth factor-ß effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor. Mol Vis 2010;16:1880–1892.
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286–1292.
   PubMed Web of Science ®Google Scholar
• Cordeiro MF. Role of transforming growth factor beta in conjunctival scarring. Clin Sci 2003;104:181–187.
   Google Scholar
• Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990;9:963–969.
   PubMed Web of Science ®Google Scholar
• Saika S, Yamanaka O, Baba Y, Kawashima Y, Shirai K, Miyamoto T et al. Accumulation of latent transforming growth factor-beta binding protein-1 and TGF beta 1 in extracellular matrix of filtering bleb and of cultured human subconjunctival fibroblasts. Graefes Arch Clin Exp Ophthalmol 2001;239:234–241.
   PubMedGoogle Scholar
• Lee DA. Drug delivery device. United StatesPatent No. 4863457, 1989.
   Google Scholar
• Prata JA Jr, Minckler DS, Mermoud A, Baerveldt G. Effects of intraoperative mitomycin-C on the function of Baerveldt glaucoma drainage implants in rabbits. J Glaucoma 1996;5:29–38.
   PubMedGoogle Scholar
• Wang ZY, Stern IJ. Disposition in rats of a polyoxypropylene-polyoxyethylene copolymer used in plasma fractionation. Drug Metab Dispos 1975;3:536–542.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee JE, Baek WY, Lim JO. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo. J Control Release 2004;96:1–7.
   PubMed Web of Science ®Google Scholar
• Johnston TP, Miller SC. Toxicological evaluation of poloxamer vehicles for intramuscular use. J Parenter Sci Technol 1985;39:83–89.
   PubMedGoogle Scholar
• Henry RL, Schmolka IR. Burn wound covering and the use of poloxamer preparations. Crit Rev Biocompatibility 1989;5:207–220.
   Google Scholar
• Garcia Sagrado F, Guzman M, Molpereces J, Aberturas MR. Pluronic copolymers-characteristics properties and pharmaceutical applications: part II. Pharm Technol Europe 1994;38–44.
   Google Scholar
• Miller S, Donovan M. Effect of Poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharm 1982;12:147–152.
   Web of Science ®Google Scholar
• Saettone MF, Giannaccini B, Delmonte G, Campigli V, Tota G, La Marca F. Solubilization of tropicamide by poloxamers: physicochemical data and activity data in rabbits and humans. Int J Pharm 1988;43(1–2):67–76.
   Google Scholar
• Desai SD, Blanchard J. Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model. J Pharm Sci 1998;87:1190–1195.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Artificial tear solutions. Int Ophthalmol Clin 1973;13:221–229.
   PubMedGoogle Scholar
• Habib FS, Attia MA. Comparative study of the ocular activity in rabbit eyes of adrenaline bitartrate formulated carbopol and poloxamers gels. Arch Pharm Chem Sci 1984;12:91–96.
   Google Scholar
• Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 2000;69:379–388.
   PubMed Web of Science ®Google Scholar
• Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 1998;6:105–112.
   PubMed Web of Science ®Google Scholar
• Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 2006;7:67.
   PubMed Web of Science ®Google Scholar
• Choi HG, Oh YK, Kim CK. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int J Pharm 1998;165:23–32.
   Web of Science ®Google Scholar
• Gong CY, Shi S, Dong PW, Zheng XL, Fu SZ, Guo G, Yang JL, Wei YQ, Qian ZY. In vitro drug release behavior from a novel thermosensitive composite hydrogel based on Pluronic F127 and poly(ethylene glycol)-poly(ϵ-caprolactone)-poly(ethylene glycol) copolymer. BMC Biotechnology 2009;9:8. Available at http://www.biomedcentral.com/1472–6750/9/8
   Google Scholar